Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Tuesday, 09'th Dec 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio to Participate in Upcoming Investor Conferences
04:01pm, Monday, 24'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Friday, 07'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio to Participate in Upcoming Investor Conferences
07:31am, Friday, 07'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
06:36pm, Wednesday, 05'th Nov 2025
Gossamer Bio (GOSS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.14 per share a year ago.
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
04:01pm, Wednesday, 05'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm
- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD - PALO ALTO, Calif. , Sept. 25
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
07:31am, Monday, 22'nd Sep 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Wednesday, 10'th Sep 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout
09:50am, Tuesday, 09'th Sep 2025
GOSS's Seralutinib remains its main value driver. This is an inhaled TKI for PAH and PH-ILD. Seralutinib's PROSERA Phase 3 trial is now fully enrolled with 6MWD as its primary endpoint. We should get
Gossamer Bio to Present at Upcoming Investor Conferences
07:31am, Friday, 29'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Thursday, 07'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates
06:56pm, Tuesday, 05'th Aug 2025
Gossamer Bio (GOSS) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.22 per share a year ago.
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
04:01pm, Tuesday, 05'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm
